Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Nature Biotechnology

Volumn 23, Issue 8, 2005, Pages 1002-1007

  Morrissey, David V ^a   Lockridge, Jennifer A ^a   Shaw, Lucinda ^a   Blanchard, Karin ^a   Jensen, Kristi ^a   Breen, Wendy ^a   Hartsough, Kimberly ^a   Machemer, Lynn ^a   Radka, Susan ^a   Jadhav, Vasant ^a   Vaish, Narendra ^a   Zinnen, Shawn ^a   Vargeese, Chandra ^a   Bowman, Keith ^a   Shaffer, Chris S ^a   Jeffs, Lloyd B ^b   Judge, Adam ^b   MacLachlan, Ian ^b   Polisky, Barry ^a  

^a Sirna Therapeutics Inc   (United States)

^b Protiva Biotherapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; BIOTECHNOLOGY; CHEMICAL MODIFICATION; DRUG DOSAGE; LIPIDS; VIRUSES;

ANTIHBV ACTIVITY; DOSE-DEPENDENT; DOSING FREQUENCY; IN VIVO ACTIVITY;

RNA;

LIPID; LIPOSOME; SMALL INTERFERING RNA; VIRUS DNA; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; FEMALE; GENE TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; FEMALE; GENE TARGETING; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIPOSOMES; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS; RNA VIRUSES;

EID: 23444445660     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1122     Document Type: Article

References (19)

1. Chiu, Y.L. & Rana, T.M. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-1048 (2003).
2. Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771 (2004).
3. Morrissey, D.V. et al. Activity of stabilized siRNAs in a mouse model of HBV replication. Hepatology 41, 1349-1356 (2005).
4. Ambegia, E. et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta 1669, 155-163 (2005).
5. Bally, M., Mayer, L., Hope, M. & Nayar, R. Pharmacodynamics of liposomal drug carriers: methodological considerations, in Liposome Technology, vol. III, 27-41, (CRC Press, London, 1993).
6. Fenske, D.B., MacLachlan, I. & Cullis, P. Long circulating vectors for the systemic delivery of genes. Curr. Opin. Mol. Ther. 3, 153-158 (2001).
7. Fenske, D.B., MacLachlan, I. & Cullis, P.R. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 346, 36-71 (2002).
8. Judge, A. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Net. Biotechnol. 23, 457-462 (2005).
9. Hornung, V. et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270 (2005).
10. Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258-1266 (1999).
11. Yang, P.L., Althage, A., Chung, J. & Chisari, F.V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 99, 13825-13830 (2002).
12. Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778-809 (2001).
13. Kim, D.H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321-325 (2004).
14. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
15. Wincott, F. et al. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23, 2677-2684 (1995).
16. Wheeler, J.J. et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6, 271-281 (1999).
17. Jeffs, L. et al. A scalable, extrusion free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22, 362-372 (2005).
18. Sandberg, J.A. et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40, 1462-1469 (2000).
19. Buckwold, V.E., Xu, Z., Chen, M., Yen, T.S. & Ou, J.H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845-5851 (1996).